Maximizing the Potential of Liver Fibrosis Assay
Drug discovery is a complex and challenging process that requires a significant investment of time, resources, and expertise. One [...]
A Closer Look at Visikol’s Liver Fibrosis Assay
Traditionally, animal models have been used to study the effects of drugs in living organisms. However, there are differences [...]
Human Liver Diseases and Hepatocyte In Vitro Cell Culture Model
The human liver is a remarkable organ with vital functions that impact metabolism, detoxification, and protein synthesis. Understanding liver [...]
Human Hepatocyte Spheroid Model to Study NASH
Non-alcoholic steatohepatitis (NASH) is a progressive disease which results in advancement of liver fibrosis, cirrhosis, and hepatocellular carcinoma, for which [...]
An In-Depth Look at PCLS Models
Non-alcoholic fatty liver disease (NAFLD) is the most chronic form of liver disease, which affects about quarter of the [...]
The Advantage of Using Visikol Assays to Study NASH
Non-alcoholic fatty liver disease (NAFLD) is a common condition and estimates indicate almost 1 in 4 adults in the [...]
Visikol to present at SELECTBIO’s December 2021 Conference
Visikol's Director of Drug Discovery, Peter Worthington Ph.D., to Present at SELECTBIO's 3D-Cell Culture, Organoids, and Organs-on-Chips Conference [...]
Assessing Promising NASH Compounds
Nonalcoholic steatohepatitis (NASH) is a disease of the liver characterized by inflammation, cell injury and fibrosis. Progression of this [...]
Visikol, Corning and Molecular Devices NASH 3D Cell Culture Webinar
Did you miss our NASH 3D cell culture webinar with Corning and Molecular Devices on October 14th? If [...]
Visikol, Corning and Molecular Devices NASH 3D Cell Culture Webinar – October 14th
In this webinar, we’ve partnered with Molecular Devices and Corning to present a case study for integrating novel [...]